CYTOF (Altamira Therapeutics) Institutional Ownership: 0.29% (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Altamira Therapeutics Institutional Ownership?

Altamira Therapeutics CYTOF -0.01% Institutional Ownership is 0.29% as of Aug. 01, 2026. The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Altamira Therapeutics's institutional ownership is 0.29%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Altamira Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Altamira Therapeutics's Float Percentage Of Total Shares Outstanding is 99.57%.

Altamira Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Altamira Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altamira Therapeutics Institutional Ownership Chart

Altamira Therapeutics Historical Data

The historical data trend for Altamira Therapeutics can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 0.14 0.10 0.10 0.10 0.08 0.08 0.07 0.06 0.06 0.06

Altamira Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.29% mean?
Altamira Therapeutics (CYTOF) has a Institutional Ownership of 0.29% as of Aug. 01, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Altamira Therapeutics and its competitors.
Is Altamira Therapeutics' Institutional Ownership too high?
Altamira Therapeutics' current Institutional Ownership is 0.29%.
How does Altamira Therapeutics' Institutional Ownership compare to CARM and PTIX?
Altamira Therapeutics' Institutional Ownership of 0.29% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Altamira Therapeutics and its competitors. Altamira Therapeutics's current Institutional Ownership is 0.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altamira Therapeutics stock overvalued right now?
Altamira Therapeutics (CYTOF) has a current Institutional Ownership of 0.29%. The current Institutional Ownership is 0.29%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Altamira Therapeutics (CYTOF), the current Institutional Ownership is 0.29% as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Altamira Therapeutics Business Description

Address 2 Church Street, Clarendon House, Hamilton, BMU, HM11
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.